Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P van Meerbeeck

Showing results (191-200 of 250) with videos related to

Pageof 25
Sort By:
European Journal of Cancer Care|August 24, 2017
Patterns of care for non-small cell lung cancer patients in Belgium: A population-based studyL Verleye, C De Gendt, F Vrijens, et al.
Clinical Lung Cancer|January 13, 2019
Prognostic Understanding and Quality of Life in Patients With Advanced Lung Cancer: A Multicenter StudyAnnelies Janssens, Sofia Derijcke, Daniëlle Galdermans, et al.
Lung Cancer (Amsterdam, Netherlands)|June 3, 2008
EBUS-TBNA for the diagnosis of central parenchymal lung lesions not visible at routine bronchoscopyKurt G Tournoy, Robert C Rintoul, Jan P van Meerbeeck, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 6, 2007
Systemic therapy of bronchioloalveolar carcinoma: results of the first IASLC/ASCO consensus conference on bronchioloalveolar carcinomaMark G Kris, Giuseppe Giaccone, Angela Davies, et al.
The European Respiratory Journal|June 8, 2010
Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trialP E Van Schil, P Baas, R Gaafar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 23, 2019
Reply to K. Masuda et alDean A Fennell, Paul Taylor, David Gilligan, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 16, 2011
Soluble mesothelin, megakaryocyte potentiating factor, and osteopontin as markers of patient response and outcome in mesotheliomaKevin Hollevoet, Kristiaan Nackaerts, Robert Gosselin, et al.
The Lancet. Oncology|June 7, 2024
Dendritic cells loaded with allogeneic tumour cell lysate plus best supportive care versus best supportive care alone in patients with pleural mesothelioma as maintenance therapy after chemotherapy (DENIM): a multicentre, open-label, randomised, phase 2/3 studyJoachim G Aerts, Robert Belderbos, Paul Baas, et al.
American Journal of Respiratory Cell and Molecular Biology|February 21, 2004
Proteomic analysis of exosomes isolated from human malignant pleural effusionsMartin P Bard, Joost P Hegmans, Annabrita Hemmes, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 17, 2012
Initial analysis of the international association for the study of lung cancer mesothelioma databaseValerie W Rusch, Dorothy Giroux, Catherine Kennedy, et al.
Pageof 25

Showing results (191-200 of 250) with videos related to

Sort By:
Pageof 25
European Journal of Cancer Care|August 24, 2017
Patterns of care for non-small cell lung cancer patients in Belgium: A population-based studyL Verleye, C De Gendt, F Vrijens, et al.
Clinical Lung Cancer|January 13, 2019
Prognostic Understanding and Quality of Life in Patients With Advanced Lung Cancer: A Multicenter StudyAnnelies Janssens, Sofia Derijcke, Daniëlle Galdermans, et al.
Lung Cancer (Amsterdam, Netherlands)|June 3, 2008
EBUS-TBNA for the diagnosis of central parenchymal lung lesions not visible at routine bronchoscopyKurt G Tournoy, Robert C Rintoul, Jan P van Meerbeeck, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 6, 2007
Systemic therapy of bronchioloalveolar carcinoma: results of the first IASLC/ASCO consensus conference on bronchioloalveolar carcinomaMark G Kris, Giuseppe Giaccone, Angela Davies, et al.
The European Respiratory Journal|June 8, 2010
Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trialP E Van Schil, P Baas, R Gaafar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 23, 2019
Reply to K. Masuda et alDean A Fennell, Paul Taylor, David Gilligan, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 16, 2011
Soluble mesothelin, megakaryocyte potentiating factor, and osteopontin as markers of patient response and outcome in mesotheliomaKevin Hollevoet, Kristiaan Nackaerts, Robert Gosselin, et al.
The Lancet. Oncology|June 7, 2024
Dendritic cells loaded with allogeneic tumour cell lysate plus best supportive care versus best supportive care alone in patients with pleural mesothelioma as maintenance therapy after chemotherapy (DENIM): a multicentre, open-label, randomised, phase 2/3 studyJoachim G Aerts, Robert Belderbos, Paul Baas, et al.
American Journal of Respiratory Cell and Molecular Biology|February 21, 2004
Proteomic analysis of exosomes isolated from human malignant pleural effusionsMartin P Bard, Joost P Hegmans, Annabrita Hemmes, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 17, 2012
Initial analysis of the international association for the study of lung cancer mesothelioma databaseValerie W Rusch, Dorothy Giroux, Catherine Kennedy, et al.
Pageof 25